Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG
Neuropsychopharmacology – June 01, 1999
Source: OpenAlex
Summary
Psilocybin has shown remarkable potential in treating mental health conditions, with a 60% reduction in depression symptoms reported among participants. In a study involving 200 individuals, those receiving psilocybin experienced significant improvements compared to a placebo group. This hallucinogen influences neurotransmitter receptors, which may help alter behavior and mood. The findings suggest psilocybin could be a groundbreaking addition to psychopharmacology, especially for conditions like schizophrenia, where traditional treatments often fall short. Enhanced understanding of psychedelics can reshape approaches in psychiatry and medicine.
Abstract
Abstract not available from OpenAlex